EvaluatePharma 报告,2013,孤儿药引领制药业的未来(Orphan Drug).pdfVIP

Orphan Drug repOrt 2013 april 2013 Welcome to the evaluatepharma® Orphan Drug report 2013 ® The first edition of EvaluatePharma ’s Orphan Drug Report brings together many of our analyses to provide top-level insight, from the world’s financial markets, into the expected performance of the orphan drug market between now and 2018. Based on EvaluatePharma® ’s coverage of over 4,000 of the world’s leading pharmaceutical and biotech companies, the Orphan Drug Report 2013 highlights trends in prescription sales for orphan vs. non-orphan drugs, orphan designation analysis in US and Europe, product and company performance, phase III RD spend and return on investment. Additional copies are available at: /orphandrug2013. Since 1996 EvaluatePharma® has been providing senior decision makers within the pharmaceutical industry with an essential service that models the sector from the viewpoint of the world’s financial markets. EvaluatePharma® ’s forward-looking view of the market is hugely influential as it displays the consensus of expectations, which influence company stock market valuations. The forecasts of equity analysts reveal their perspectives on individual company performance, industry trends and the macro economic environment. EvaluatePharma® has captured the consensus forecasts of equity analysts and seamlessly integrated them with the historic results, as reported by companies. From this comprehensive view of the industry, its past and expected future performance emerg